TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 1450309

Group type: EXPERIMENTAL
Intervention: PCA device Prominject with fentanyl demand doses of 34 micrograms, lockout time of 1 min, no concurrent infusion
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: PCA device ODAC with fentanyl demand doses of 34.5 micrograms, lockout time of 5 min, fixed-rate infusion of 4 micrograms/h
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: PCA device Prominject with tail-dose, fixed-rate infusion of 17 mg/h for a maximum of 60 minutes following a valid demand
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: PCA device ODAC with adaptive-rate infusion starting with 4 micrograms/h, adapted to individual needs
Number of subjects: 80
Study: 6421429

Group type: EXPERIMENTAL
Intervention: Hypertonic diet with an osmolality of 430 mmol/kg (group 1)
Number of subjects: 118

Group type: EXPERIMENTAL
Intervention: Diet with osmolality increasing from 145 to 430 mmol/kg over the first four days (group 2)
Number of subjects: 118

Group type: EXPERIMENTAL
Intervention: Isotonic diet (300 mmol/kg) (group 3)
Number of subjects: 118

Group type: COMPARATOR
Intervention: All diets (group 1, group 2, group 3)
Number of subjects: 118

Group type: COMPARATOR
Intervention: Concurrent treatment with antibiotics
Number of subjects: 118
Study: 3555277

Group type: EXPERIMENTAL
Intervention: 10 mg oral bisacodyl
Number of subjects: 45

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 45
Study: 31758523

Group type: EXPERIMENTAL
Intervention: Comprehensive rehabilitation and intensive education (CRIE) program
Number of subjects: 300

Group type: COMPARATOR
Intervention: Usual care (UC) group
Number of subjects: 300
Study: 31322838

Group type: EXPERIMENTAL
Intervention: Alutard SQ (Dp extracts)
Number of subjects: 230

Group type: EXPERIMENTAL
Intervention: NovoHelisen Depot (NHD; Dp/Df extracts)
Number of subjects: 230
Study: 28753075

Group type: EXPERIMENTAL
Intervention: Directive messages
Number of subjects: 199

Group type: COMPARATOR
Intervention: Autonomy support
Number of subjects: 199
Study: 26578326

Group type: EXPERIMENTAL
Intervention: Parenting intervention
Number of subjects: 51
Study: 23307845

Group type: EXPERIMENTAL
Intervention: EB/TBA (14 mg estradiol benzoate and 100 mg trenbolone acetate)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: EB (14 mg estradiol benzoate)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: TBA (100 mg trenbolone acetate)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Sham-implanted control (SC)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: EB/TBA
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: TBA
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: EB and TBA
Number of subjects: 12
Study: 21138981

Group type: EXPERIMENTAL
Intervention: eGFR ≥60
Number of subjects: 86

Group type: EXPERIMENTAL
Intervention: eGFR 59‐30
Number of subjects: 86

Group type: EXPERIMENTAL
Intervention: eGFR <30
Number of subjects: 86
Study: 18438255

Group type: EXPERIMENTAL
Intervention: Strength training (total body session, circuit fashion, 7 exercises, 3 circuits of 8 to 12 RM, abdominal exercise 15 to 20 RM)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 20
Study: 17070196

Group type: EXPERIMENTAL
Intervention: Letrozole (2.5 mg/d)
Number of subjects: 74

Group type: COMPARATOR
Intervention: Clomiphene citrate (CC) (100 mg/d)
Number of subjects: 74
Study: 12075708

Group type: EXPERIMENTAL
Intervention: Clear topical ointment
Number of subjects: 40

Group type: COMPARATOR
Intervention: Control group (no ointment)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Both groups (treatment and control)
Number of subjects: 40
Study: 9861383

Group type: EXPERIMENTAL
Intervention: Triclabendazole, 5 mg/kg once daily for 3 days
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: Triclabendazole, 10 mg/kg twice on one day
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: Triclabendazole, 10 mg/kg in a single dose
Number of subjects: 62

Group type: COMPARATOR
Intervention: Praziquantel, 25 mg/kg thrice daily for 3 days
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: All treatment groups
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: Triclabendazole
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: By day 90
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: Single dose of 10 mg/kg
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: By day 365
Number of subjects: 62
Study: 7632447

Group type: EXPERIMENTAL
Intervention: IMPACT program (enhanced intervention program)
Number of subjects: 252

Group type: COMPARATOR
Intervention: Regular screening and referral group (control)
Number of subjects: 252
Study: 2167564

Group type: EXPERIMENTAL
Intervention: SHBV
Number of subjects: 20

Group type: COMPARATOR
Intervention: smallpox vaccine
Number of subjects: 20
Study: 736080

Group type: EXPERIMENTAL
Intervention: Regular drops of 10% phenylephrine HCl and 1.0% cyclopentolate HCl or 1.0% tropicamide HCl
Number of subjects: 0

Group type: COMPARATOR
Intervention: Microdrops (0.005 or 0.01 ml) of a mixture of 5% phenylephrine HCl and 0.5% tropicamide HCl
Number of subjects: 0

Group type: COMPARATOR
Intervention: Regular drops of mixtures of 1% phenylephrine HCl or 0.4% hydroxyamphetamine hydrobromide with 0.1% cyclopentolate HCl or 0.1% tropicamide
Number of subjects: 0

Group type: COMPARATOR
Intervention: Diluted solutions (0.005 or 0.01 ml)
Number of subjects: 0
Study: 29064343

Group type: EXPERIMENTAL
Intervention: FMS-based functional exercise plus routine rehabilitation (Group 1)
Number of subjects: 38

Group type: COMPARATOR
Intervention: Routine rehabilitation only (Group 2)
Number of subjects: 38
Study: 27449546

Group type: EXPERIMENTAL
Intervention: Pharmacist-led intervention
Number of subjects: 101

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 101
Study: 25842934

Group type: EXPERIMENTAL
Intervention: Human-related kidney transplantation (group 1, 50 patients)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Cadaver kidney transplantation (group 2, 30 patients)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Cadaver kidney transplantation with rapid recovery (group 2a, 20 patients)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Cadaver kidney transplantation with delayed recovery (group 2b, 10 patients)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Hemodialysis sessions in group 2b
Number of subjects: 80
Study: 23208965

Group type: EXPERIMENTAL
Intervention: Hypocaloric commercial formula (Optisource®) - 1109.3 kcal/day, 166.4 g carbohydrates, 63 g proteins, 21.3 g lipids
Number of subjects: 40

Group type: COMPARATOR
Intervention: Conventional nutritional advice (decrease 500 cal/day)
Number of subjects: 40
Study: 20833591

Group type: EXPERIMENTAL
Intervention: Cilostazol (100 mg twice daily)
Number of subjects: 2757

Group type: COMPARATOR
Intervention: Aspirin (81 mg once daily)
Number of subjects: 2757
Study: 18656091

Group type: EXPERIMENTAL
Intervention: Atorvastatin 10mg daily
Number of subjects: 2838

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2838
Study: 17094914

Group type: EXPERIMENTAL
Intervention: PRAC combined with preoperative radiotherapy (radiochemotherapy group)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Preoperative radiotherapy alone (radiotherapy group)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Operation alone (control group)
Number of subjects: 60
Study: 12829200

Group type: EXPERIMENTAL
Intervention: Combination therapy with hydrocortisone (5 mg/d) and fludrocortisone (50 microg/d)
Number of subjects: 100
Study: 10484047

Group type: EXPERIMENTAL
Intervention: Total homocysteine (tHcy) levels in subjects with neuropathy
Number of subjects: 452

Group type: EXPERIMENTAL
Intervention: Total homocysteine (tHcy) levels in subjects with macroalbuminuria
Number of subjects: 452

Group type: EXPERIMENTAL
Intervention: Correlation of tHcy with serum creatinine
Number of subjects: 452

Group type: EXPERIMENTAL
Intervention: Correlation of tHcy with creatinine clearance
Number of subjects: 452

Group type: EXPERIMENTAL
Intervention: Correlation of tHcy with serum B12
Number of subjects: 452

Group type: EXPERIMENTAL
Intervention: Correlation of tHcy with folate
Number of subjects: 452

Group type: EXPERIMENTAL
Intervention: Correlation of tHcy with MMA
Number of subjects: 452

Group type: EXPERIMENTAL
Intervention: Correlation of tHcy with cystathionine
Number of subjects: 452
Study: 8759408

Group type: EXPERIMENTAL
Intervention: Transvaginal color and pulsed Doppler measurements
Number of subjects: 40
Study: 1771395

Group type: EXPERIMENTAL
Intervention: Ketoprofen, 200 mg/day (50 mg q.i.d.) for 7 days
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study: 7276189

Group type: EXPERIMENTAL
Intervention: Monitoring‐Contract (MC)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Monitoring (M)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Attention‐Placebo (AP)
Number of subjects: 0
Study: 30588849

Group type: EXPERIMENTAL
Intervention: Active 'blue' lighting intervention (λmax = 480 nm)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Placebo 'red' control (λmax = 640 nm)
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Both intervention and control conditions
Number of subjects: 32
Study: 26408395

Group type: EXPERIMENTAL
Intervention: Menthol mouth rinse (MEN) during exercise
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Ice slurry ingestion (ICE) before exercise
Number of subjects: 11

Group type: COMPARATOR
Intervention: No intervention (CON)
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Menthol mouth rinse (MEN)
Number of subjects: 11
Study: 25159886

Group type: EXPERIMENTAL
Intervention: Lisdexamfetamine dimesylate 20 mg
Number of subjects: 135

Group type: EXPERIMENTAL
Intervention: Lisdexamfetamine dimesylate 50 mg
Number of subjects: 135

Group type: EXPERIMENTAL
Intervention: Lisdexamfetamine dimesylate 70 mg
Number of subjects: 135

Group type: EXPERIMENTAL
Intervention: Armodafinil 250 mg
Number of subjects: 135

Group type: EXPERIMENTAL
Intervention: Active treatments (Lisdexamfetamine dimesylate and Armodafinil)
Number of subjects: 135

Group type: EXPERIMENTAL
Intervention: Lisdexamfetamine dimesylate and Armodafinil
Number of subjects: 135
Study: 22754899

Group type: EXPERIMENTAL
Intervention: Autologous bone (group A)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Porcine bone in addition to autologous bone (group B)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Both groups (A and B)
Number of subjects: 16
Study: 20140088

Group type: EXPERIMENTAL
Intervention: Optimal waist-to-hip ratio (approximately 0.7) with redistributed body fat
Number of subjects: 0

Group type: COMPARATOR
Intervention: Presurgical bodies (not optimal WHR)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Changes in BMI
Number of subjects: 0
Study: 18541739

Group type: EXPERIMENTAL
Intervention: Toothbrushing
Number of subjects: 290

Group type: EXPERIMENTAL
Intervention: Single-tooth extraction with amoxicillin prophylaxis
Number of subjects: 290

Group type: COMPARATOR
Intervention: Single-tooth extraction with identical placebo
Number of subjects: 290
Study: 16003653

Group type: EXPERIMENTAL
Intervention: Creatine monohydrate (10 g/d x 10 d presurgery to 5 g/d x 30 d postsurgery)
Number of subjects: 37

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 37
Study: 12404668

Group type: EXPERIMENTAL
Intervention: Mirtazapine
Number of subjects: 3
Study: 10811324

Group type: COMPARATOR
Intervention: Euglycemia (blood glucose, 6 mmol/L)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Hyperglycemia (blood glucose, 15 mmol/L)
Number of subjects: 10
Study: 8665134

Group type: EXPERIMENTAL
Intervention: Graduated hookwire for localization of impalpable breast lesions
Number of subjects: 31

Group type: COMPARATOR
Intervention: Conventional mammographic localizing wire
Number of subjects: 31
Study: 1800430

Group type: EXPERIMENTAL
Intervention: Combined oral contraceptives (OC) with levonorgestrel (LNG) and norethisterone acetate (NEA)
Number of subjects: 622

Group type: EXPERIMENTAL
Intervention: Combined oral contraceptives (OC) with levonorgestrel (LNG)
Number of subjects: 622

Group type: COMPARATOR
Intervention: Women not on OC (control group)
Number of subjects: 622
Study: 6616495

Group type: EXPERIMENTAL
Intervention: 5-FU
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: FAC (5-FU, doxorubicin, and cyclophosphamide)
Number of subjects: 51
Study: 31044688

Group type: EXPERIMENTAL
Intervention: Overall survival
Number of subjects: 275

Group type: EXPERIMENTAL
Intervention: Response to treatment
Number of subjects: 275

Group type: EXPERIMENTAL
Intervention: Stabilization of tumor growth
Number of subjects: 275

Group type: EXPERIMENTAL
Intervention: Nausea/vomiting
Number of subjects: 275

Group type: EXPERIMENTAL
Intervention: Diarrhea
Number of subjects: 275
Study: 28256485

Group type: EXPERIMENTAL
Intervention: System B/Obtura
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Matched-single-cone
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Cold lateral compaction with matched GP cone
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Lateral compaction with standardized GP cones
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Thermafil filling
Number of subjects: 150
Study: 26603258

Group type: EXPERIMENTAL
Intervention: GSK2126458 (GSK458) at a maximum tolerated dose (MTD) of 2.5 mg once daily or twice daily dosing.
Number of subjects: 170

Group type: EXPERIMENTAL
Intervention: GSK2126458 (GSK458) at doses ranging from 0.1 to 3 mg once or twice daily.
Number of subjects: 170

Group type: EXPERIMENTAL
Intervention: GSK2126458 (GSK458) at a maximum tolerated dose (MTD) of 2.5 mg once daily.
Number of subjects: 170

Group type: EXPERIMENTAL
Intervention: GSK2126458 (GSK458) in patients with PIK3CA mutations.
Number of subjects: 170
Study: 25170037

Group type: EXPERIMENTAL
Intervention: Osteopathic manipulative therapy (OMTh)
Number of subjects: 44

Group type: COMPARATOR
Intervention: Sham therapy (control)
Number of subjects: 44
Study: 22183158

Group type: EXPERIMENTAL
Intervention: Intravenous magnesium 50 mg kg(‐1)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Isotonic saline (control)
Number of subjects: 20
Study: 20382272

Group type: EXPERIMENTAL
Intervention: Transdermal drug delivery system (TDDS) of Carvedilol (CRV)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Transdermal drug delivery system (TDDS) of Hydrochlorothiazide (HCTZ)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Conventional immediate release oral tablets of Carvedilol (CRV)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Conventional immediate release oral tablets of Hydrochlorothiazide (HCTZ)
Number of subjects: 10
Study: 17284744

Group type: EXPERIMENTAL
Intervention: Daily supplement containing folate (1 mg), vitamin B‐12 (500 microg), and vitamin B‐6 (10 mg)
Number of subjects: 276

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 276
Study: 16084158

Group type: EXPERIMENTAL
Intervention: Losartan 50 mg once daily
Number of subjects: 3152

Group type: COMPARATOR
Intervention: Captopril 50 mg 3 times daily
Number of subjects: 3152
Study: 12047326

Group type: EXPERIMENTAL
Intervention: 3-day triple therapy for H. pylori eradication
Number of subjects: 108

Group type: EXPERIMENTAL
Intervention: 7-day triple therapy for H. pylori eradication
Number of subjects: 108

Group type: COMPARATOR
Intervention: H. pylori stool antigen before therapy
Number of subjects: 108

Group type: COMPARATOR
Intervention: H. pylori stool antigen after therapy
Number of subjects: 108
Study: 9989681

Group type: EXPERIMENTAL
Intervention: 1 MJ (340 mL) alcohol (wine or beer)
Number of subjects: 52

Group type: COMPARATOR
Intervention: fat (cream fruit juice), protein (protein fruit juice), carbohydrate (grape juice)
Number of subjects: 52

Group type: COMPARATOR
Intervention: water
Number of subjects: 52

Group type: COMPARATOR
Intervention: no preload
Number of subjects: 52
Study: 8216442

Group type: EXPERIMENTAL
Intervention: Glimepiride (0.25 mg)
Number of subjects: 1

Group type: EXPERIMENTAL
Intervention: Glimepiride (0.50 mg)
Number of subjects: 1

Group type: EXPERIMENTAL
Intervention: Glimepiride (1.25 mg)
Number of subjects: 1

Group type: EXPERIMENTAL
Intervention: Glimepiride (1.50 mg)
Number of subjects: 1
Study: 3677789

Group type: EXPERIMENTAL
Intervention: Combination inhaler therapy (salbutamol and beclomethasone dipropionate)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Separate inhaler therapy (salbutamol and beclomethasone dipropionate)
Number of subjects: 18
Study: 29307750

Group type: EXPERIMENTAL
Intervention: MRSA isolates
Number of subjects: 173

Group type: COMPARATOR
Intervention: MSSA isolates
Number of subjects: 173
Study: 26413853

Group type: EXPERIMENTAL
Intervention: FTC/TDF (Tenofovir-Emtricitabine)
Number of subjects: 2499

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2499

Group type: EXPERIMENTAL
Intervention: Vaccination offered to individuals susceptible to HBV
Number of subjects: 2499
Study: 24965573

Group type: COMPARATOR
Intervention: Baricitinib (1-20 mg single ascending doses, 2-20 mg QD, 5 mg BID for 10 or 28 days)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Baricitinib
Number of subjects: 0
Study: 23046071

Group type: EXPERIMENTAL
Intervention: Omeprazole
Number of subjects: 142

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 142
Study: 20530324

Group type: EXPERIMENTAL
Intervention: IFNbeta-1b 50 microg
Number of subjects: 372

Group type: EXPERIMENTAL
Intervention: IFNbeta-1b 250 microg
Number of subjects: 372

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 372

Group type: EXPERIMENTAL
Intervention: IFNbeta-1b (both dosages)
Number of subjects: 372

Group type: EXPERIMENTAL
Intervention: NAbs to IFNbeta-1b
Number of subjects: 372

Group type: EXPERIMENTAL
Intervention: NAb status
Number of subjects: 372
Study: 19107071

Group type: EXPERIMENTAL
Intervention: N-acetyl-aspartyl glutamic acid (NAAGA) monotherapy over 4 weeks
Number of subjects: 102

Group type: COMPARATOR
Intervention: Bi-therapy (NAAGA and Levocabastine during the first week, then NAAGA only for the next 3 weeks)
Number of subjects: 102
Study: 16602173

Group type: EXPERIMENTAL
Intervention: Individualised counselling and follow‐up telephone calls from an exercise scientist (ES) without a pedometer (G3)
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Individualised counselling and follow‐up telephone calls from an exercise scientist (ES) with a pedometer (G2)
Number of subjects: 28

Group type: COMPARATOR
Intervention: Brief verbal and written advice from a general practitioner (GP) (G1)
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: All groups combined
Number of subjects: 28
Study: 11933906

Group type: EXPERIMENTAL
Intervention: D/Sense 2 + Prime & Bond 2.1
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: D/Sense 2 + Bistite II SC
Number of subjects: 16

Group type: COMPARATOR
Intervention: Prime & Bond 2.1 (no D/Sense 2 treatment)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Bistite II SC (no D/Sense 2 treatment)
Number of subjects: 16
Study: 12349021

Group type: EXPERIMENTAL
Intervention: Spermicidal preparations containing nonoxynol-9 (gel products with varying amounts)
Number of subjects: 1800

Group type: EXPERIMENTAL
Intervention: Suppository tablet and film preparation
Number of subjects: 1800
Study: 8721468

Group type: EXPERIMENTAL
Intervention: i.m. ketorolac (30 mg)
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: i.v. ketorolac (30 mg)
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: intrawound (i.w.) ketorolac (30 mg)
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: p.o. ketorolac (30 mg)
Number of subjects: 70

Group type: COMPARATOR
Intervention: Control group (no ketorolac)
Number of subjects: 70
Study: 1888644

Group type: EXPERIMENTAL
Intervention: Flupirtine 200 mg administered perorally
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Flupirtine (various doses)
Number of subjects: 0
Study: 6356971

Group type: EXPERIMENTAL
Intervention: 0.4 mg sublingual buprenorphine
Number of subjects: 74

Group type: EXPERIMENTAL
Intervention: 0.3 mg intramuscular buprenorphine
Number of subjects: 74

Group type: EXPERIMENTAL
Intervention: 10 mg intramuscular morphine
Number of subjects: 74

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 74
Study: 31138281

Group type: EXPERIMENTAL
Intervention: Cardiovascular rehabilitation program (heating, aerobic exercise, muscle strengthening) for 45 min, three times a week, for 16 weeks.
Number of subjects: 40

Group type: COMPARATOR
Intervention: Conventional physiotherapy for 45 min, three times a week, for 16 weeks.
Number of subjects: 40
Study: 28842370

Group type: EXPERIMENTAL
Intervention: 40 mg methylprednisolone acetate (MP)
Number of subjects: 48

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 48
Study: 24528544

Group type: EXPERIMENTAL
Intervention: Paracetamol
Number of subjects: 53

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 53

Group type: EXPERIMENTAL
Intervention: Exercise
Number of subjects: 53
Study: 24907224

Group type: EXPERIMENTAL
Intervention: Simeprevir (150 mg once daily, orally), peginterferon alfa 2a (180 μg once weekly, subcutaneous injection) or 2b (according to bodyweight), plus ribavirin (1000‐1200 mg/day or 800‐1400 mg/day, orally)
Number of subjects: 391

Group type: COMPARATOR
Intervention: Placebo (once daily, orally), peginterferon alfa 2a or 2b, plus ribavirin
Number of subjects: 391

Group type: EXPERIMENTAL
Intervention: Simeprevir group
Number of subjects: 391

Group type: COMPARATOR
Intervention: Placebo group
Number of subjects: 391
Study: 22925325

Group type: EXPERIMENTAL
Intervention: Probiotics (Lactobacillus GG; ATCC 53103; 1 × 10(10) colony-forming units daily)
Number of subjects: 191

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 191
Study: 19757048

Group type: EXPERIMENTAL
Intervention: Balsalazide 3 g/d (n = 38)
Number of subjects: 86

Group type: COMPARATOR
Intervention: Placebo (n = 37)
Number of subjects: 86

Group type: EXPERIMENTAL
Intervention: Balsalazide 3 g/d
Number of subjects: 86

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 86
Study: 17517301

Group type: EXPERIMENTAL
Intervention: Facial sensory retraining exercises in conjunction with standard opening exercises
Number of subjects: 186

Group type: COMPARATOR
Intervention: Standard opening exercises alone
Number of subjects: 186
Study: 15364042

Group type: EXPERIMENTAL
Intervention: Lamotrigine (400 mg/day)
Number of subjects: 38

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 38
Study: 11435055

Group type: EXPERIMENTAL
Intervention: Continuous modified glucose-insulin-potassium infusion
Number of subjects: 48

Group type: COMPARATOR
Intervention: Intermittent intravenous (IV) insulin injections
Number of subjects: 48
Study: 9526936

Group type: EXPERIMENTAL
Intervention: Oral clonidine (300 microg)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Intramuscular (i.m.) clonidine (300 microg)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Epidural clonidine (300 microg)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Control (placebo)
Number of subjects: 80